The effect of royal jelly supplementation on hormonal status,insulin resistance and inflammatory factors in patients with polycystic ovary syndrome

Phase 2

Conditions: Polycystic ovary syndrome.
Polycystic ovarian syndrome
E28.2

Registration Number: IRCT20190212042686N3

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 24

Inclusion Criteria

Female volunteers aged 15-45 with clinical symptoms of hyperandrogenism

Exclusion Criteria

Pregnancy
Breastfeeding
Having diseases such as autoimmune diseases
Digestive diseases
Liver disease
Thyroid
Unstable cardiovascular diseases
Severe respiratory disease (Asthma and Chronic bronchitis)
Taking any type of vitamin and mineral supplements in the last six months
People with a history of allergies

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Estrogen. Timepoint: Baseline and 2 months after the treatment. Method of measurement: ELISA Test.;Testosterone. Timepoint: Baseline and 2 months after the treatment. Method of measurement: ELISA Test.;Sex Hormone-Binding Globulin (SHBG). Timepoint: Baseline and 2 months after the treatment. Method of measurement: ELISA Test.;Fasting blood sugar. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Insulin resistance with HOMA-IR score. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Interleukin 6. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Hs-CRP. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Body mass scale. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Weight scale and stadiometer.

Secondary Outcome Measures